These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30498418)

  • 1. Current Status and Future Perspectives of Axillary Management in the Neoadjuvant Setting.
    Kühn T; Classe JM; Gentilini OD; Tinterri C; Peintinger F; de Boniface J
    Breast Care (Basel); 2018 Oct; 13(5):337-341. PubMed ID: 30498418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
    Schwartz GF; Tannebaum JE; Jernigan AM; Palazzo JP
    Cancer; 2010 Mar; 116(5):1243-51. PubMed ID: 20087958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy - a retrospective study.
    Coufal O; Zapletal O; Gabrielová L; Fabian P; Schneiderová M
    Rozhl Chir; 2018; 97(12):551-557. PubMed ID: 30646734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Evolving Role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for Node-Positive Breast Cancer: Systematic Review and Pooled Analysis.
    Swarnkar PK; Tayeh S; Michell MJ; Mokbel K
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33810544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer.
    DeSnyder SM; Mittendorf EA; Le-Petross C; Krishnamurthy S; Whitman GJ; Ueno NT; Woodward WA; Kuerer HM; Akay CL; Babiera GV; Yang W; Lucci A
    Clin Breast Cancer; 2018 Feb; 18(1):e73-e77. PubMed ID: 28755879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA study.
    Hartmann S; Kühn T; Hauptmann M; Stickeler E; Thill M; Lux MP; Fröhlich S; Ruf F; Loibl S; Blohmer JU; Kolberg HC; Thiemann E; Weigel M; Solbach C; Kaltenecker G; Paluchowski P; Schrauder MG; Paepke S; Watermann D; Hahn M; Hufnagel M; Lefarth J; Untch M; Banys-Paluchowski M;
    Geburtshilfe Frauenheilkd; 2022 Sep; 82(9):932-940. PubMed ID: 36110892
    [No Abstract]   [Full Text] [Related]  

  • 7. Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary results.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2019 Sep; 30():52-57. PubMed ID: 31500785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
    Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
    Reitsamer R; Peintinger F; Rettenbacher L; Prokop E
    J Surg Oncol; 2003 Oct; 84(2):63-7. PubMed ID: 14502778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy.
    Kang YJ; Han W; Park S; You JY; Yi HW; Park S; Nam S; Kim JH; Yun KW; Kim HJ; Ahn SH; Park S; Lee JE; Lee ES; Noh DY; Lee JW
    Breast Cancer Res Treat; 2017 Nov; 166(2):473-480. PubMed ID: 28766131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study.
    van Nijnatten TJA; Simons JM; Smidt ML; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef K; Koppert LB; Luiten EJT
    Clin Breast Cancer; 2017 Aug; 17(5):399-402. PubMed ID: 28487053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
    Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
    Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer.
    Zetterlund LH; Frisell J; Zouzos A; Axelsson R; Hatschek T; de Boniface J; Celebioglu F
    Breast Cancer Res Treat; 2017 May; 163(1):103-110. PubMed ID: 28224384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients?
    Marrazzo A; Taormina P; Gebbiab V; David M; Riili I; Lo Gerfo D; Casà L; Noto A
    Chir Ital; 2007; 59(5):693-9. PubMed ID: 18019642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node biopsy does not apply to all axillary lymph node-positive breast cancer patients after neoadjuvant chemotherapy.
    Ge WK; Yang B; Zuo WS; Zheng G; Dai YQ; Han C; Yang L; Zheng MZ
    Thorac Cancer; 2014 Nov; 5(6):550-5. PubMed ID: 26767051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT).
    Peppe A; Wilson R; Pope R; Downey K; Rusby J
    Breast; 2017 Oct; 35():104-108. PubMed ID: 28704697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
    Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
    Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel lymph node biopsy after previous axillary surgery: A review.
    Kothari MS; Rusby JE; Agusti AA; MacNeill FA
    Eur J Surg Oncol; 2012 Jan; 38(1):8-15. PubMed ID: 22032909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.